ENTA is a sleeper entrant in the HBV arena. ENTA’s proven drug-discovery expertise in viral/liver diseases gives me confidence that their HBV core inhibitor will be a good one.
Among the new MoAs being tested by the various players are:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.